Gilead Science: Remdesivir is still active against the Opmikharong variant

Recently, Gilead Sciences analyzed the existing genetic information of the SARS-CoV-2 Semiconon variant and found that no new universal mutations were found in the viral RNA polymerase compared with the previous mutated strains. This suggests that Remdesivir (Veklury®) is still active against the Opmicron variant. Gilead will conduct laboratory tests to confirm the results of this analysis. Remdesivir is the standard antiviral therapy for hospitalized patients with COVID-19 and can help reduce disease progression in patients of all severities.